Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15807803 | 1.00 | IDO1 (0.46) | IDO1TACR1NR3C1PGRNR3C2 | |
| SCHEMBL19971042 | 0.85 | IDO1 (0.43) | IDO1MEN1KMT2ALTA4HHCRTR1 | |
| SCHEMBL15804495 | 0.85 | IDO1 (0.43) | IDO1MEN1KMT2ALTA4HHCRTR1 | |
| SCHEMBL5763376 | 0.84 | NR3C1 (0.42) | IDO1NR3C1PGRNR3C2MEN1 | |
| SCHEMBL22035469 | 0.84 | LMNA (0.43) | TACR1PTGS2MAPTMEN1KMT2A | |
| SCHEMBL28572692 | 0.84 | LMNA (0.43) | TACR1PTGS2MAPTMEN1KMT2A | |
| SCHEMBL29671128 | 0.84 | LMNA (0.43) | TACR1PTGS2MAPTMEN1KMT2A | |
| SCHEMBL25184594 | 0.83 | KDM4E (0.59) | IDO1PTGS2MAPTMEN1KMT2A | |
| SCHEMBL22113081 | 0.83 | NLRP3 (0.45) | IDO1MEN1KMT2ALMNATSHR | |
| SCHEMBL2586006 | 0.83 | NLRP3 (0.45) | IDO1MEN1KMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190308943-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | PARION SCIENCES, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-10246425-B2 | 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds | PARION SCIENCES, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170362187-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | PARION SCIENCES, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9695134-B2 | 3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-2-carboxamide compounds | PARION SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9593084-B2 | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity | PARION SCIENCES, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150299142-A1 | 3,5-DIAMINO-6-CHLORO-N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2-CARBOXAMIDE COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9029382-B2 | 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds | PARION SCIENCES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140170244-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | PARION SCIENCES, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140073788-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130338164-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | ELAN PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-1150997-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-1147091-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1144364-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000051974-A1 | ALPHA-AMINOACETIC ACID DERIVATIVES USEFUL AS ALPHA 4 BETA 7 - RECEPTOR ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| CN-1265657-A | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| WO-2000043371-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000043354-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000043415-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-1000051-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170244-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | CFTR, SCNN1B, SCN5A | IDO1 3005/4885TACR1 893/4885NR3C1 2986/4885 |
| US-20140073788-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | MANBA, OAT, PIGO | IDO1 2811/4885TACR1 3516/4885NR3C1 4104/4885 |
| US-20150299142-A1 | 3,5-DIAMINO-6-CHLORO-N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2-CARBOXAMIDE COMPOUNDS | CFTR, SCNN1B, SCN5A | IDO1 3307/4885TACR1 1011/4885NR3C1 2869/4885 |
| US-20190308943-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | CFTR, SCNN1B, SCN5A | IDO1 3005/4885TACR1 893/4885NR3C1 2986/4885 |
| US-20170362187-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | CFTR, SCNN1B, SCN5A | IDO1 3005/4885TACR1 893/4885NR3C1 2986/4885 |
| US-20130338164-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | VCAM1, ICAM1, ITGB4 | IDO1 2173/4885TACR1 1015/4885NR3C1 1554/4885 |
| US-10246425-B2 | 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds | CFTR, SCNN1B, SCN5A | IDO1 3005/4885TACR1 893/4885NR3C1 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.